Targeting the neuro–immune axis: immunological mechanisms and therapeutic strategies in male sexual dysfunction Authors: Zheng Hu, Jun Luo, Jianyun Lou, Juntao Deng, Zi tao Gong, Jinming Chen Published: 2026 ABSTRACT AbstractMale sexual dysfunction (MSD) is a multifactorial condition in which traditional models focusing on vascular, endocrine, and psychogenic factors are insufficient. Emerging evidence highlights dysregulated crosstalk between the nervous and immune systems—the neuroimmune axis—as a potential unifying pathological substrate. This review synthesizes fragmented yet compelling evidence linking neural injury, chronic inflammation (both systemic and neurogenic), and immune dysregulation to the pathogenesis of MSD. We propose a novel integrative framework in which disruption of the neuro-immune axis serves as a convergent pathway for diverse etiologies, ranging from diabetic neuropathy to chronic pelvic pain. Central to this framework is the concept that immune-mediated processes exacerbate neural and vascular damage, creating a self-perpetuating cycle of dysfunction. Building on this mechanistic perspective, we explore the translational potential of neurosurgical and neuromodulatory strategies—such as sacral neuromodulation and vagus nerve stimulation—to restore neuroimmune homeostasis. Although direct clinical evidence in MSD remains limited, insights from related fields, including chronic pain and autoimmune disorders, provide a strong rationale for further investigation. This review aims to bridge mechanistic insights with therapeutic innovation, charting a course for future research into precision neuromodulation as a promising frontier for refractory MSD.Keywords: MSD, Neuro–immune axis, Neurogenic inflammation, Neuromodulation, Chronic inflammation, Neuroimmunology Introduction MSD represents one of the most prevalent yet highly heterogeneous disease spectra in andrology and reproductive medicine. It encompasses erectile dysfunction, premature ejaculation, ejaculatory disorders, and decreased libido as distinct but often overlapping clinical phenotypes [1]. Studies consistently demonstrate a progressive increase in MSD prevalence with advancing age, with a markedly higher burden observed in individuals with metabolic syndrome, cardiovascular disease, neurological disorders, and chronic inflammatory conditions [2]. Beyond its detrimental impact on quality of life and psychological well-being, MSD has increasingly been recognized as a systemic health indicator, closely associated with elevated risks of cardiovascular events, depressive disorders, and all-cause mortality [3]. Consequently, MSD has emerged as a growing public health concern rather than merely a quality-of-life–related condition. Current therapeutic strategies for MSD remain largely symptom-oriented. Phosphodiesterase type 5 inhibitors, hormone replacement therapy, and psychobehavioral interventions provide clinical benefits in selected patient populations; however, their efficacy is often limited in individuals with neurogenic sexual dysfunction, chronic inflammatory conditions, or metabolic comorbidities. Furthermore, contraindications, suboptimal treatment responses, and poor long-term tolerability are common in these groups [4, 5]. These limitations strongly suggest that conventional vascular-, endocrine-, or psychology-centered models fail to capture the full complexity of MSD pathophysiology, which likely involves multisystem dysregulation and intricate inter-organ communication. The nervous system plays a central integrative role in the initiation, maintenance, and termination of the male sexual response cycle [6]. Through coordinated hypothalamic–spinal–peripheral neural circuits, the central nervous system integrates sexual stimuli with emotional, motivational, and endocrine signals, while the autonomic nervous system precisely regulates penile hemodynamics and ejaculatory reflexes [7]. Increasing evidence, however, indicates that neural function does not operate in isolation; rather, it is profoundly influenced by local and systemic immune states. Immune-mediated inflammatory processes, immunometabolic regulation, and tissue repair mechanisms directly modulate neural plasticity, neurotransmission efficiency, and vascular endothelial integrity [8, 9]. Recent experimental and clinical studies have underscored the critical role of chronic low-grade inflammation, neurogenic inflammation, and immune homeostatic imbalance in the development and progression of MSD. Aberrant activation of immune cells and the sustained release of inflammatory mediators not only impair endothelial function but also alter neuronal excitability, neurotransmitter release, and neurovascular coupling, thereby exacerbating erectile and ejaculatory dysfunction [10, 11]. Despite these insights, existing research has predominantly focused on isolated pathways or localized mechanisms, resulting in fragmented evidence and a lack of a unifying theoretical framework that integrates neural regulation with immune dysregulation. The concept of the neuro–immune axis offers a compelling theoretical framework for understanding MSD. However, the field faces two critical challenges that impede clinical translation. First, the evidence linking specific neuro–immune dysregulations to distinct MSD phenotypes remains fragmented and often indirect, primarily derived from preclinical models or studies of comorbid conditions. Second, although neuromodulation shows promise in modulating immune function, its application in MSD remains experimental, with a lack of robust, controlled clinical trials to establish efficacy and define patient selection criteria. [12, 13]. To address these gaps, this review has three primary objectives: (1) to systematically synthesize the available preclinical and clinical evidence, constructing a plausible and testable neuro-immune axis framework for MSD; (2) to critically evaluate the emerging rationale—rather than established efficacy—for applying neuromodulatory interventions based on this framework; and (3) to identify key knowledge gaps and propose future research directions that prioritize translational validation. By framing neuromodulation not as a current solution but as a mechanism-guided frontier, we aim to stimulate interdisciplinary research that moves beyond symptomatic management toward etiology-targeted, precision therapy for MSD. Given the heterogeneity of MSD, this review will primarily focus on erectile dysfunction (ED) as the best-studied phenotype within the proposed neuro-immune framework. Where evidence permits, we will also discuss the implications for ejaculatory dysfunction, particularly in the context of chronic pelvic pain, and for decreased libido as it relates to central neuroinflammation. This focused approach allows for a more coherent and in-depth exploration of the underlying mechanisms. Neural regulation of male sexual function Male sexual function is governed by highly coordinated interactions among the central nervous system, the autonomic nervous system, and peripheral somatic nerves, operating with precise temporal and spatial integration [14]. This complex regulatory network not only facilitates fundamental physiological reflexes but also integrates higher-order cognitive, emotional, and motivational processes, ultimately resulting in coherent sexual behavior [15]. Central regulatory systems: integration of cognition, motivation, and reflexes Supraspinal Centers (Forebrain) The prefrontal cortex and limbic system serve as the primary regulatory centers for sexual motivation, fantasy, social cue interpretation, and behavioral inhibition [16]. Limbic structures, including the amygdala and nucleus accumbens, link emotional states—such as pleasure, reward, stress, and threat—to sexual stimuli, while the prefrontal cortex oversees contextual evaluation and executive decision-making [17]. The hypothalamus, particularly the medial preoptic area, functions as a critical neuroendocrine integrator by integrating gonadal hormone signals (e.g., testosterone and estradiol) with multimodal neural inputs. It receives affective and motivational information from limbic circuits and projects to brainstem and spinal sexual centers to regulate erection and ejaculation. Through this gating function, the hypothalamus links psychological states with peripheral physiological responses, playing a pivotal role in the initiation and maintenance of sexual behavior [18, 19]. Midbrain and brainstem centers: periaqueductal gray matter The periaqueductal gray (PAG) serves as a crucial integrative hub connecting forebrain structures and the hypothalamus with brainstem autonomic nuclei and spinal centers. It receives descending inputs from regions associated with emotion and threat, modulating nociception, cardiovascular activity, respiration, micturition, and defensive behaviors [20]. Notably, the PAG also plays a pivotal role in descending pain inhibition, emotional regulation, and the coordination of autonomic functions, including those critical for reproductive behaviors [21]. Spinal regulatory centers: autonomic and rhythmic generators Sacral Erectile Center (S2–S4) This center contains parasympathetic preganglionic neurons that innervate the pelvic organs via the pelvic nerve and cavernous nerves [22]. It integrates sensory afferent input from genital structures with descending supraspinal modulation. Upon sexual stimulation, parasympathetic terminals release nitric oxide and other vasodilatory mediators, inducing smooth muscle relaxation, arterial dilation, and penile erection [23, 24]. Thoracolumbar Sympathetic Center (T11–L2) This center innervates the male reproductive tract and bladder neck through the hypogastric nerve and pelvic plexus. It plays a key role in psychogenic erection and the modulation of sexual arousal, especially when sacral pathways are impaired. Its primary function is to control the emission phase of ejaculation by mediating contractions of the vas deferens, seminal vesicles, and prostate, which propel seminal fluid into the prostatic urethra. While the epididymis also contains smooth muscle, its contribution to the forceful, rhythmic expulsion characteristic of ejaculation is minimal [25]. Additionally, post-ejaculatory sympathetic activation promotes detumescence [26]. Onuf's Nucleus (S2–S4 Ventral Horn) Onuf's nucleus consists of a specialized group of somatic motor neurons that innervate the bulbospongiosus, ischiocavernosus, and external urethral and anal sphincter muscles through the pudendal nerve. In males, these perineal striated muscles contribute to maintaining erection and facilitating ejaculation by producing rhythmic contractions at the base of the penis [27, 28]. Peripheral neural pathways: the final common pathway Cavernous nerves Originating from the pelvic (inferior hypogastric) plexus, the cavernous nerves provide the primary autonomic innervation to the corpora cavernosa and proximal urethra. These delicate fibers descend along the posterolateral neurovascular bundles of the prostate and enter the corpora cavernosa near the prostatic apex and membranous urethra [29]. The integrity of these nerves is essential for endothelial function and nitric oxide release, making them the critical substrate in neurogenic erectile dysfunction [30]. Pudendal nerve The pudendal nerve is a mixed nerve that provides both somatic sensory and motor innervation. Its dorsal penile branch transmits fine touch, vibration, and erotic sensations from the glans penis, while its motor branches innervate the pelvic floor muscles essential for ejaculatory function [31]. Pelvic and hypogastric nerves The pelvic (parasympathetic) and hypogastric (sympathetic) nerves form a pelvic plexus that innervates pelvic organs [32]. Irreversible injury to this plexus is a major complication of pelvic surgeries, such as radical prostatectomy and rectal cancer resection. Key neurochemical mediators: molecular foundations of signaling Neural signal transmission relies on precisely regulated neurotransmitter systems, which also serve as therapeutic targets. Pro-erectile mediators include nitric oxide—the primary vasodilatory signal released from cavernous nerve terminals and endothelial cells [33]. As well as acetylcholine and vasoactive intestinal peptide, which work synergistically with nitric oxide to promote erection [34]. Anti-erectile or detumescence-associated mediators, such as norepinephrine and endothelin-1, induce smooth muscle contraction and penile flaccidity [5, 35]. Sensory and modulatory neuropeptides, including calcitonin gene-related peptide and substance P, are involved in nociceptive and sensory transmission and are closely linked to sexual pleasure [36]. Central neuromodulators, such as dopamine, serotonin, and oxytocin, significantly influence sexual desire, arousal, and satisfaction [37]. An integrated neurovascular–endocrine perspective Male sexual function exemplifies a prototypical neurovascular-endocrine integration model. Neural initiation translates cognitive or sensory stimuli into neural signals; vascular execution converts these signals into endothelial and smooth muscle responses that enable penile blood filling [33].Hormonal modulation—particularly by testosterone—maintains neural structural integrity and signal transduction efficiency at multiple levels, including the hypothalamus and corpora cavernosa [38]. Emerging evidence further indicates that local immune cells and inflammatory mediators directly influence cavernous nerve function and endothelial health, forming a "neuro-immune-vascular" triad. This paradigm offers a novel framework for understanding sexual dysfunction associated with diabetes, aging, and chronic inflammatory conditions [39, 40]. Summary Neural regulation of male sexual function is a highly sophisticated, multilevel system that extends from higher cognitive centers to peripheral effector organs. The cavernous nerve, serving as the final common pathway connecting central commands to target tissues, represents a critical point of vulnerability. Disruption of this system due to disease, injury, or aging creates conditions for neuro-immune interactions to emerge as key pathological drivers of sexual dysfunction. The following section focuses on how immune dysregulation alters this neural framework and contributes to MSD pathogenesis. This figure illustrates the multi-level regulatory system governing male sexual function, encompassing the central nervous system (forebrain, hypothalamus, midbrain, and brainstem), spinal regulatory centers (thoracolumbar sympathetic center, sacral erection center, Onuf's nucleus), and peripheral neural pathways (cavernous nerve, pudendal nerve). Arrows indicate the direction of neural signal transmission. Dashed boxes highlight the modulatory roles of key neurotransmitters and hormones. Immune components have been added to illustrate the "neuro-immune-vascular" tripartite dialogue: macrophage and mast cell icons are placed near peripheral nerves and cavernosal tissue, and inflammatory cytokines (TNF-α, IL-6) are shown as modulators of endothelial function and neural signaling. Dashed arrows from immune cells to neural/vascular structures represent the regulatory influence of the local immune microenvironment on functional homeostasis. The role of the immune system in MSD Traditionally, the role of the immune system in andrological disorders has been largely limited to infectious conditions, such as prostatitis. However, emerging evidence suggests that disruption of immune homeostasis—particularly chronic, low-grade, non-infectious inflammation—serves as a central pathological mechanism linking neural injury, vascular dysfunction, and MSD [10]. This process primarily affects these conditions through coordinated dysregulation of the neural, vascular, and endocrine axes [41]. Systemic chronic inflammation: an independent risk factor and common underlying cause of erectile dysfunction Systemic chronic inflammatory states, characterized by elevated circulating levels of C-reactive protein, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), are commonly observed in obesity, metabolic syndrome, diabetes mellitus, and cardiovascular disease–-conditions that represent the most prevalent comorbidities of ED [42, 43]. In these conditions, inflammation is not merely a correlate but a mechanistic driver of erectile dysfunction. For instance, in type 2 diabetes, elevated IL-6 and TNF-α are directly linked to endothelial dysfunction through suppression of endothelial nitric oxide synthase and increased oxidative stress. Longitudinal studies have demonstrated that higher baseline CRP levels predict the subsequent development of ED, independent of other cardiovascular risk factors [44]. Furthermore, emerging evidence suggests that gut microbiota dysbiosis may contribute to ED through systemic inflammation and endothelial dysfunction, providing an additional link between inflammatory states and sexual function [45]. Mechanism I: direct endothelial injury Pro-inflammatory cytokines, such as TNF-α and IL-1β, activate the NF-κB signaling pathway within endothelial cells. This activation leads to the upregulation of endothelin-1, suppression of endothelial nitric oxide synthase expression and activity, and increased production of reactive oxygen species. Collectively, these changes result in endothelial dysfunction and a significant reduction in nitric oxide bioavailability, representing a critical step in disrupting the vascular foundation necessary for penile erection [46, 47]. Mechanism ii: promotion of cavernosal fibrosis Within an inflammatory microenvironment, profibrotic mediators such as transforming growth factor-β are activated, driving the phenotypic transition of cavernosal smooth muscle cells into myofibroblasts and accelerating extracellular matrix deposition. This fibrotic remodeling reduces cavernosal compliance, making adequate erection unattainable even in the presence of sufficient arterial inflow [48, 49]. The neuro-immune interface: from neuroinflammation to immune-mediated neuropathy Autoimmune neuropathies In autoimmune peripheral neuropathies, such as Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy, autoantibodies and autoreactive T cells target peripheral nerve myelin, nodal and paranodal proteins, or axonal structures. This immune-mediated damage can affect the pudendal or cavernous nerves, resulting in impaired nerve conduction velocity and subsequent sexual dysfunction [50]. Immune surveillance and pathological activation in peripheral nerves Resident immune cells, particularly macrophages within the dorsal root ganglia and pelvic nerves, undergo pathological activation following nerve injury, shifting from a reparative M2 phenotype to a pro-inflammatory M1 phenotype. These cells release elevated levels of IL-1β and TNF-α, which directly suppress neuronal action potentials and disrupt axonal transport [51]. Schwann cells, the principal glial cells of the peripheral nervous system, also undergo phenotypic changes after injury, adopting a repair-supportive role that initially includes clearing debris and secreting inflammatory mediators to recruit macrophages. However, under pathological conditions, this process can become dysregulated, contributing to prolonged inflammation and impaired regeneration [52]. Immunometabolism and oxidative stress: amplifiers of a pathological feedback loop Under metabolic stress conditions such as hyperglycemia and dyslipidemia, immune and metabolic pathways become tightly interconnected, forming a self-reinforcing pathological loop [53]. Immune cells undergo metabolic reprogramming, with macrophages preferentially adopting glycolytic metabolism that drives pro-inflammatory polarization and sustained cytokine production [54]. The accumulation of advanced glycation end products further activates immune cells through receptor-mediated signaling, exacerbating oxidative stress and inflammation [55]. Oxidative stress, as a downstream effector of inflammation, directly impairs mitochondrial function and axonal integrity in neurons while simultaneously suppressing nitric oxide signaling, thereby perpetuating the "inflammation–oxidative stress–functional impairment" loop [56]. Local immune microenvironment and chronic pelvic pain syndrome Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) serves as a prototypical model of neuro-immune interaction-driven sexual dysfunction [57]. An initial infection or physical injury activates nociceptive nerve endings within the prostate, triggering the release of neuropeptides such as substance P and calcitonin gene-related peptide through TRPV1–NaV1.8 signaling pathways. These neuropeptides initiate neurogenic inflammation and modulate immune cell responses, establishing the basis for chronic inflammation and pain [58]. Acting as "alarmins," these neuropeptides directly activate mast cells and macrophages, inducing degranulation and the release of histamine, tryptase, and other inflammatory mediators, thereby amplifying neurogenic inflammation. Persistent inflammation sensitizes peripheral nerve endings (peripheral sensitization) and activates spinal dorsal horn glial cells, including microglia and astrocytes, leading to central sensitization [59]. Consequently, minimal pelvic stimuli are perceived as pain during sexual activity (dyspareunia), while spinal interneuronal interactions suppress normal sexual reflex integration, resulting in erectile dysfunction, premature ejaculation, or reduced libido [60]. It is important to note that the most direct evidence supporting this neurogenic inflammation pathway comes from studies of chronic prostatitis/chronic pelvic pain syndrome (CPPS). The extent to which identical mechanisms operate in other MSD phenotypes, such as psychogenic ED or diabetic ED, without concomitant pelvic pain, remains an open question requiring further investigation (Fig. 1). Integrated neurovascular-endocrine regulatory network of male sexual function The immune system as an integrator and effector Collectively, the immune system plays a dual role in MSD. As an integrator, it converges diverse etiological factors—including metabolic dysfunction, neural injury, and vascular risk—into a common endpoint of chronic inflammation. As an effector, it mediates tissue injury through the release of cytokines, reactive oxygen species, and other mediators that directly damage neural, vascular, and cavernosal structures (Tables 1 and 2). Table 1Linking MSD phenotypes to neuro-immune mechanismsMSD PhenotypeProposed Dominant Neuro-Immune Mechanism(s)Strength of Evidence in MSDErectile Dysfunction (ED)Endothelial dysfunction driven by systemic inflammation; Neurogenic inflammation in cavernous nerves; Impaired nerve repair post-injuryModerate (Preclinical & Epidemiological)Ejaculatory DysfunctionCentral sensitization and autonomic dysregulation in CPPS; Neurogenic inflammation affecting seminal vesicle/prostate innervationWeak (Primarily inferred from CPPS models)Decreased Libido/AnhedoniaCentral neuroinflammation affecting mesolimbic reward circuits (e.g., microglial activation in response to chronic stress or systemic inflammation)Hypothesized (Based on depression and chronic pain literature)Pain during Sexual ActivityPeripheral and central sensitization driven by neurogenic inflammation and spinal glial cell activation in CPPSModerate (Clinical and preclinical CPPS studies) Linking MSD phenotypes to neuro-immune mechanisms Table 2Comparison of pathological mechanisms: traditional view vs. neuro-immune axis perspectiveComparative DimensionTraditional ViewNeuro-Immune Axis PerspectivePathological CoreVascular, Hormonal, PsychologicalNeuro-Immune Regulatory ImbalanceRole of InflammationSecondary or Concurrent FactorCore DriverTherapeutic TargetsPDE5 Inhibitors, HormonesNeuromodulation, ImmunomodulationIntervention StrategySymptomatic TreatmentEtiology-Based Regulation, Systemic InterventionTypical Disease ModelArterial ED, Psychogenic EDDiabetic ED, Chronic Pelvic Pain SyndromeThis table compares the differences in pathological mechanisms, therapeutic targets, and intervention strategies between traditional views and the neuro-immune axis perspectiveED Erectile dysfunction, PDE5 Phosphodiesterase type 5 Comparison of pathological mechanisms: traditional view vs. neuro-immune axis perspective This table compares the differences in pathological mechanisms, therapeutic targets, and intervention strategies between traditional views and the neuro-immune axis perspective ED Erectile dysfunction, PDE5 Phosphodiesterase type 5 Neuro-immune axis mechanisms in MSD: a systematic pathological framework Bidirectional communication between the nervous and immune systems constitutes a central regulatory mechanism in maintaining male sexual homeostasis. Dysregulation of this neuro-immune axis has emerged as a unifying pathological paradigm that can explain sexual dysfunction arising from diverse etiologies [61]. This framework encompasses four interrelated mechanistic layers (Figs. 2 and 3). Neuro-immune axis mechanisms in MSD: evidence levels Precision intervention pathway for MSD based on the neuroimmune axis This figure systematically illustrates four core mechanisms through which dysregulation of the neuro-immune axis may lead to MSD: ① initiation of neurogenic inflammation and deterioration of the local microenvironment; ② immune dysregulation and fibrosis during peripheral nerve repair; ③ imbalance of autonomic-immune homeostasis and systemic inflammation; ④ central neuroinflammation and disruption of higher-order control. The figure depicts a pathological cascade from peripheral to central levels. Evidence level is indicated by line style Solid lines represent mechanisms with direct evidence from MSD-specific studies or validated animal models (e.g., cavernous nerve injury models). Dashed lines represent mechanisms primarily supported by evidence from related fields (e.g., chronic pain, diabetes, depression) or general neurobiology, which provide a strong rationale for investigation in MSD but require direct validation. Dotted lines represent hypothesized connections based on neuroimmune principles, with no direct evidence currently available in MSD. Neurogenic inflammation: initiation of a local injury cycle Neurogenic inflammation is initiated by the sustained release of neuropeptides, such as substance P and calcitonin gene-related peptide, from sensory nerve terminals. These mediators activate mast cells, macrophages, and endothelial cells, triggering a sterile Through retrograde neural sensitization, this process establishes a self-perpetuating loop of local injury and inflammation. While well-characterized in other tissues, the specific role of neurogenic inflammation within the corpora cavernosa as a driver of erectile dysfunction is an emerging area of investigation. Preclinical evidence suggests that sensory nerve endings in the pelvic region can release neuropeptides that may contribute to a local inflammatory milieu, but direct evidence within the penis itself remains limited [62, 63]. Immune dysregulation during peripheral nerve repair: regeneration versus fibrosis Successful repair of peripheral nerves, including the cavernous nerve, critically depends on a tightly coordinated immune response [64]. Macrophages and Schwann cells serve as the primary mediators of this process. In the immediate aftermath of a cavernous nerve injury, macrophages initially exhibit a pro-inflammatory (M1) phenotype, clearing debris. This is crucial for subsequent repair, as a timely transition to an anti-inflammatory, reparative (M2) phenotype is necessary to support Schwann cell-mediated axonal regeneration. Under pathological conditions such as diabetes or chronic compression, however, this M1 to M2 transition is impaired, with macrophages adopting a persistent pro-inflammatory M1 phenotype and Schwann cells exhibiting impaired reparative capacity [65, 66]. This imbalance hinders axonal regeneration and promotes fibrotic scar formation, resulting in permanent disruption of neural signal transmission and irreversible functional loss. Autonomic–immune imbalance: a systemic pathological basis The autonomic nervous system directly regulates both systemic and local immune responses. Chronic stress and disease states are marked by persistent sympathetic overactivation and receptor imbalances, which modify immune cell cytokine profiles viaβ1/β2-adrenergic signaling. This alteration promotes pro-inflammatory mediators, such as IL-17A, and disrupts the anti-inflammatory balance, thereby fostering low-grade chronic inflammation and increasing susceptibility to autoimmune diseases [67]. Across chronic diseases and aging, sympathetic hyperactivity is often accompanied by impairment of the vagal–cholinergic anti-inflammatory pathway, resulting in a state of "pro-inflammatory dominance with insufficient anti-inflammatory counterbalance." This systemic and pelvic inflammatory microenvironment damages endothelial function and microcirculation, further compromises neural regeneration, and makes the neurovascular unit increasingly vulnerable to persistent injury [68]. Central neuroinflammation and disruption of higher-order control: the final common pathway Central neuroinflammation refers to inflammatory processes within the brain and spinal cord, orchestrated by resident glial cells. Microglia, the brain's resident macrophages, can be activated by peripheral inflammatory signals or neuronal stress signals (e.g., from chronic pelvic pain), adopting a pro-inflammatory phenotype that releases cytokines like IL-1β and TNF-α. Astrocytes, in turn, can become reactive, losing their supportive functions and potentially releasing neurotoxic factors. This glial activation can profoundly alter synaptic transmission and neural circuit function. Peripheral and systemic neuroimmune disturbances ultimately propagate to the central nervous system. Microglia and astrocytes within the spinal cord and brain become aberrantly activated in response to inflammatory or stress-related signals, releasing central inflammatory mediators [69]. This leads to two critical outcomes. First, disruption of midbrain–limbic dopaminergic reward circuits and associated synaptic plasticity remodels neural networks governing sexual motivation and pleasure, resulting in decreased libido and anhedonia [70]. This is hypothesized to occur through microglia-mediated synaptic pruning and altered dopamine signaling in the nucleus accumbens, a mechanism observed in animal models of chronic stress-induced depression. Second, activation of spinal dorsal horn glial cells promotes central sensitization, heightening responsiveness to pelvic afferent input while simultaneously impairing the integration of normal sexual reflex arcs, thereby contributing to dyspareunia and complex sexual dysfunction syndromes [71]. Section summary Together, these four mechanistic layers constitute a complete pathological loop, progressing from local initiation via neurogenic inflammation, through failed peripheral nerve repair driven by immune dysregulation, evolving within a systemic autonomic–immune imbalance, and culminating in central neuroinflammatory disruption of higher-order control.. Neurosurgical interventions: innovative strategies for modulating the neuro-immune axis The recognition of the neuro-immune axis in MSD pathophysiology provides a conceptual foundation for exploring interventions that modulate this crosstalk. It is important to emphasize that, with few exceptions, the clinical application of these interventions specifically for MSD remains experimental. However, several neurosurgical and neuromodulatory techniques, developed for other indications, offer a testable mechanistic rationale based on the framework proposed in this review. This section categorizes these approaches by their primary target and the current level of evidence specifically for sexual dysfunction [72]. Table 3 summarizes these interventions with defined evidence levels. Table 3Comparison of neurosurgical intervention techniquesIntervention TechniqueTarget SiteMechanism OverviewSuitable PopulationEvidence Level in MSDDeep Brain Stimulation (DBS)Nucleus Accumbens, HypothalamusModulates reward systems; hypothesized (but unproven) effects on neuro-immune axisRefractory depression/OCD with EDAnecdotal/HypotheticalSacral Neuromodulation (SNM)S3/S4 Nerve RootsInhibits sympathetic tone, enhances parasympathetic, modulates local pelvic immunityChronic pelvic pain with EDMultiple Clinical Studies (in CPPS; no ED-specific RCTs)Vagus Nerve Stimulation (VNS)Vagus NerveActivates cholinergic anti-inflammatory pathway; reduces systemic cytokinesSystemic inflammatory diseases with EDAnimal & Preclinical/Mechanistic RationaleTranscranial Magnetic Stimulation (TMS)Prefrontal CortexModulates cortical excitability; may reduce pain and anxietyED with comorbid depression/anxietyTheoretical/Limited StudiesNerve ReconstructionCavernous NerveReconstructs neural structure; aims to optimize regenerative immune microenvironmentPost-surgical or injury-induced EDAnimal & Preclinical/Limited Clinical StudiesDBS Deep brain stimulation, SNM Sacral neuromodulation, VNS Vagus nerve stimulation, TMS Transcranial magnetic stimulation, CPPS Chronic pelvic pain syndrome, RCT Randomized controlled trial Comparison of neurosurgical intervention techniques DBS Deep brain stimulation, SNM Sacral neuromodulation, VNS Vagus nerve stimulation, TMS Transcranial magnetic stimulation, CPPS Chronic pelvic pain syndrome, RCT Randomized controlled trial Pelvic-specific neuromodulation Sacral Neuromodulation (SNM) Sacral neuromodulation (SNM) is the most extensively studied and clinically implemented neuromodulatory technique in relation to pelvic floor disorders. Chronic electrical stimulation of the S3 and S4 sacral nerve roots via implanted electrodes has proven effective in treating chronic pelvic pain and lower urinary tract dysfunction. Increasingly, its therapeutic mechanisms are being understood through a neuroimmune framework. On one hand, SNM suppresses excessive sympathetic activity while enhancing parasympathetic tone, thereby rebalancing autonomic function and establishing a systemically anti-inflammatory internal environment [73]. On the other hand, SNM may regulate the release of sensory neuropeptides, suppress local neurogenic inflammation and immune cell activation, and modulate signal transmission within the spinal dorsal horn. Through these mechanisms, SNM may inhibit microglial activation and reverse central sensitization [74]. Similarly, spinal cord stimulation, which is widely used to treat neuropathic pain following spinal cord injury, may improve regional blood flow and the local immune microenvironment below the level of injury, thereby supporting the preservation and recovery of residual neural function. Current evidence in MSD: SNM is FDA-approved for urinary and fecal incontinence. Multiple observational studies and small case series report improvements in chronic pelvic pain and associated sexual dysfunction (e.g., dyspareunia, erectile dysfunction) in both women and men [75]. However, randomized controlled trials (RCTs) specifically designed with MSD as a primary outcome measure are lacking. The degree to which improvements in sexual function result directly from pelvic neuromodulation versus indirectly from pain relief remains to be definitively established. SNM represents a promising avenue for investigation in refractory MSD, particularly when comorbid with chronic pelvic pain or lower urinary tract symptoms. Systemic anti-inflammatory neuromodulation Vagus Nerve Stimulation (VNS) The vagus nerve is the primary effector of the cholinergic anti-inflammatory pathway. Cervical VNS has been shown to significantly reduce systemic inflammatory cytokines, including TNF-α and IL-6, in both preclinical models and clinical studies [76]. In patients with sexual dysfunction comorbid with systemic inflammatory diseases, such as rheumatoid arthritis or inflammatory bowel disease, VNS presents a novel approach for systemic modulation of the neuroimmune axis and may become a future component of interdisciplinary combination therapy [77]. Current evidence in MSD: VNS is currently approved for treatment-resistant epilepsy and depression. Its ability to reduce systemic inflammation is well-established in conditions such as rheumatoid arthritis, where VNS has been shown to attenuate disease severity and cytokine production [78]. This provides a strong mechanistic rationale for hypothesizing that VNS could improve endothelial function and reduce systemic inflammation in MSD patients with comorbid inflammatory conditions. However, no clinical trials have yet tested this hypothesis in an MSD-specific population. The application of VNS for sexual dysfunction remains entirely investigational. Central neuromodulation Deep Brain Stimulation (DBS) DBS targeting reward- and motivation-related structures, such as the nucleus accumbens and the ventral striatum/anterior limb of the internal capsule (ALIC), has been reported to improve obsessive–compulsive disorder and depression. These improvements are occasionally accompanied by enhanced sexual function and reductions in medication-related sexual side effects. These effects are hypothesized to result from the reorganization of limbic–hypothalamic–pituitary circuits and the indirect modulation of neuroimmune interactions [79, 80]. However, these observations are largely incidental and the underlying mechanisms remain entirely speculative. To date, no direct evidence exists linking DBS-induced neuroimmune modulation to changes in sexual function. The available evidence on DBS and sexual function comes exclusively from studies in Parkinson's disease, where findings are inconsistent—some meta-analyses suggest improvement, while others report no significant effect on erectile function [81]. The hypothesized connection between altered limbic circuit activity, downstream effects on the hypothalamic-pituitary axis, and subsequent changes in systemic inflammation or sexual behavior remains a fertile but untested area for future research. Transcranial Magnetic Stimulation (TMS) and Transcranial Direct Current Stimulation (tDCS) As noninvasive neuromodulatory techniques, TMS and transcranial direct current stimulation (tDCS) modulate cortical excitability—particularly within prefrontal regions—and may alleviate depression and anxiety, which are commonly comorbid with sexual dysfunction. By enhancing descending inhibitory pathways, these techniques may also reduce chronic pelvic pain, thereby interrupting the vicious cycle of pain-driven functional impairment [82]. Although indirect, such central modulation may exert downstream effects on immune signaling and autonomic balance. Current evidence in MSD Studies specifically examining TMS or tDCS for MSD are extremely limited. A small number of studies have explored repetitive TMS for premature ejaculation with mixed results, but these have not been conclusively replicated. The application of these techniques to modulate neuroimmune pathways relevant to sexual function remains theoretical and requires dedicated investigation. Peripheral nerve interventions Neurolysis and nerve reconstruction Microsurgical neurolysis and nerve reconstruction aim, from a technical standpoint, to achieve precise fascicular alignment and minimize scar-related compression. Biologically, these procedures fundamentally seek to establish a temporally and spatially optimized regenerative immune microenvironment, involving coordinated interactions among M2-polarized macrophages, Schwann cells, and regenerating axons. Autologous nerve grafts, such as the sural nerve, have demonstrated the ability to recreate this favorable microenvironment in short- to medium-length defects. These principles may be applied to the functional reconstruction of pelvic nerves, including the cavernous nerves, in selected cases [83, 84]. Current evidence in MSD In the context of cavernous nerve injury during radical prostatectomy, nerve-sparing techniques and, in select cases, nerve grafting have been employed to preserve or restore erectile function [85]. However, the specific contribution of immune modulation to outcomes following cavernous nerve reconstruction remains incompletely characterized. Most evidence comes from general peripheral nerve injury models rather than pelvic-specific studies. Further research is needed to determine whether optimizing the immune microenvironment can enhance functional outcomes in cavernous nerve repair. Targeted nerve ablation Targeted nerve ablation has demonstrated favorable analgesic efficacy and safety in treating refractory chronic pelvic pain and may be understood as indirectly reducing neurogenic inflammation by downregulating aberrant neuro-immune signaling [86]. However, from the perspective of regenerative immunology, functional modulation rather than complete destruction should be prioritized. Achieving an optimal balance between analgesic benefit and preservation of sensory-immune repair mechanisms requires precise targeting, ideally guided by imaging techniques and diagnostic nerve blocks [87]. Current evidence in MSD While effective for pain relief, the impact of targeted nerve ablation on sexual function is not well-studied. Potential risks include unintended denervation that could exacerbate erectile or ejaculatory dysfunction. Therefore, this approach should be considered with caution in patients for whom preservation of sexual function is a priority, and further studies are needed to assess its risk–benefit profile in this population. Evidence level definitions Anecdotal / Hypothetical: Based on case reports, incidental findings, or theoretical rationale; no systematic studies in MSD. Multiple Clinical Studies: Supported by observational studies, case series, or small trials in patient cohorts that include MSD-related outcomes (e.g., chronic pelvic pain studies that measured sexual function). Animal & Preclinical / Mechanistic Rationale: Supported by in vivo animal models and in vitro studies relevant to MSD mechanisms, or strong rationale from other fields. Theoretical / Limited Studies: Based on mechanistic principles with very few or inconclusive studies in MSD. Translational perspectives and challenges Translating neuro-immune theory into clinical practice Despite its promise, the translation of neuro-immune concepts into clinical management faces several critical challenges that require multidisciplinary collaboration. Depth of mechanistic research Single-cell sequencing, spatial transcriptomics, and multi-omics approaches have successfully generated high-resolution neuro-immune atlases across multiple human organs, demonstrating the technical feasibility of mapping neuro-immune cellular landscapes in human tissues. However, systematic neuro-immune atlases of pelvic pathologies—such as chronic pelvic pain—remain largely unexplored and represent a high-priority frontier for interdisciplinary research [88, 89]. Absence of specific biomarkers Currently, no specific biomarkers reliably identify "neuro–immune–driven ED" or accurately predict responses to neuromodulatory interventions. Although inflammation-related immune markers offer directional insights, advances in neuromodulation and artificial intelligence provide a clear technological pathway for developing multimodal, interpretable, and clinically actionable biomarker systems [90, 91]. Precision in intervention and outcome evaluation Standardization of indications Identifying patients most likely to benefit from neurosurgical or neuromodulatory interventions requires defining mechanistic subtypes—such as immune-dominant or neuroinflammatory phenotypes—using large-scale, multimodal datasets. Differential responses to interventions should then inform indication criteria driven by objective markers rather than solely by surface symptomatology [92]. Personalization of stimulation parameters Currently, no established guidelines specify neuromodulation targets or parameters based directly on neuroimmune status. A practical approach involves integrating neuroimmune biomarkers and brain network features to guide target and rhythm selection, followed by closed-loop neuromodulation and AI-assisted optimization to explore individualized parameter combinations within safety limits [93]. Comprehensive efficacy assessment Beyond subjective questionnaires, objective measures—such as penile Doppler ultrasound, neurophysiological testing, and dynamic monitoring of systemic and local inflammatory markers—should be incorporated to quantify the effects of neuroimmune modulation. Establishment of multidisciplinary care models There is an urgent need for multidisciplinary teams—including neurosurgery, andrology/urology, rheumatology/immunology, pain medicine, and psychiatry—to develop integrated diagnostic and treatment pathways that encompass conservative management through to neurosurgical intervention. This figure illustrates a translational pathway from mechanistic research to clinical practice. The left panel depicts the construction of a pelvic neuro-immune atlas using multi-omics technologies, such as single-cell sequencing and spatial transcriptomics, to define disease subtypes. The middle panel represents individualized diagnosis and classification based on biomarkers. The right panel outlines precision intervention strategies tailored to different subtypes, including neuromodulation, immunomodulation, and nerve reconstruction. The bottom arrow indicates a closed-loop translational process encompassing "mechanism discovery → biomarker development → individualized therapy → outcome evaluation," emphasizing multidisciplinary collaboration and the integration of intelligent medical technologies. Immunomodulatory therapies: emerging strategies for MSD Beyond neuromodulation, direct immunomodulatory approaches represent a promising therapeutic frontier for MSD, particularly in subsets driven by chronic inflammation, autoimmune neuropathies, or systemic immune dysregulation. Emerging evidence suggests that targeting specific immune pathways may restore neuro-immune homeostasis and ameliorate sexual dysfunction. Cytokine-targeted therapies Biologics targeting pro-inflammatory cytokines—such as TNF-α inhibitors (e.g., infliximab, adalimumab), IL-6 receptor antagonists (e.g., tocilizumab), and IL-1β blockers (e.g., anakinra)—have demonstrated efficacy in reducing systemic inflammation and improving endothelial function in autoimmune and metabolic diseases [94]. Preliminary data from rheumatoid arthritis and inflammatory bowel disease cohorts suggest incidental improvements in sexual function, likely through attenuation of vascular inflammation and neuropathic pain [95]. In MSD associated with chronic pelvic pain or systemic inflammation, these agents may disrupt the “inflammatory–endothelial–neural” triad and represent a rationale for off-label or trial-based use [96]. Immune cell reprogramming Modulating macrophage polarization from pro-inflammatory M1 toward reparative M2 phenotypes is a key strategy in peripheral nerve regeneration. Agents such as colony-stimulating factor 1 receptor inhibitors or IL-4/IL-13-based therapies may enhance Schwann cell remyelination and axonal regrowth, potentially benefiting cavernous nerve injury-induced ED [97]. Similarly, regulatory T cell (Treg) augmentation—via low-dose IL-2 or adoptive transfer—may suppress autoreactive responses in autoimmune neuropathies affecting pelvic nerves [98]. Targeting neurogenic inflammation Substance P and calcitonin gene–related peptide receptor antagonists (e.g., gepants), as well as TRPV1/NaV1.8 channel blockers, may attenuate neurogenic inflammation and peripheral sensitization in chronic pelvic pain syndromes. These agents could concomitantly improve sexual pain and reflex integration [99, 100]. Metabolic-immune interventions In diabetic or obesity-related MSD, immunometabolic modulators–-such as SGLT2 inhibitors and GLP-1 receptor agonists–-hold promise. Their established ability to reduce systemic inflammation, oxidative stress, and advanced glycation end products in cardiovascular and metabolic diseases provides a strong rationale for hypothesizing that they could similarly improve endothelial function and, by extension, cavernosal compliance. However, this potential benefit for erectile tissue remains to be directly demonstrated in clinical trials [101]. Challenges and future directions Despite mechanistic promise, immunomodulatory therapies in MSD face several hurdles: (1) lack of validated biomarkers to identify “immune-responsive” MSD subtypes; (2) potential immunosuppressive risks versus benefit–risk assessment in non–life-threatening conditions; (3) need for organ-specific delivery to minimize systemic exposure. Future trials should stratify patients by immune profiling and integrate immunomodulation with neuromodulation in combinatorial regimens. Conclusions and future directions The neuro-immune framework provides a valuable lens through which to understand refractory MSD and suggests novel therapeutic targets. However, translation of this paradigm into clinical practice requires a dual focus on mechanistic validation and therapeutic innovation. Future research must prioritize: (1) high-resolution mapping of the pelvic neuro-immune cellular landscape in both healthy and disease states; (2) identification and validation of biomarkers capable of stratifying patients into neuro-immune subtypes; and (3) rigorous testing of mechanism-guided interventions, including neuromodulation and immunomodulation, in well-designed clinical trials. If successful, this approach could eventually pave the way for mechanism-guided, rather than purely symptomatic, therapies for MSD. We propose two interconnected strategic pillars to bridge this gap: Consolidating the mechanistic evidence baseMapping the Niche: Utilize high-resolution technologies, including single-cell sequencing and spatial transcriptomics, to characterize the pelvic neuro-immune cellular landscape in both healthy conditions and across various MSD subtypes.Biomarker Discovery and Validation: Establish well-phenotyped longitudinal cohorts to identify and validate candidate neuroimmune biomarkers capable of predicting disease trajectory, subtype classification, and potential responsiveness to immunomodulatory or neuromodulatory interventions. Consolidating the mechanistic evidence baseMapping the Niche: Utilize high-resolution technologies, including single-cell sequencing and spatial transcriptomics, to characterize the pelvic neuro-immune cellular landscape in both healthy conditions and across various MSD subtypes.Biomarker Discovery and Validation: Establish well-phenotyped longitudinal cohorts to identify and validate candidate neuroimmune biomarkers capable of predicting disease trajectory, subtype classification, and potential responsiveness to immunomodulatory or neuromodulatory interventions. Mapping the Niche: Utilize high-resolution technologies, including single-cell sequencing and spatial transcriptomics, to characterize the pelvic neuro-immune cellular landscape in both healthy conditions and across various MSD subtypes. Mapping the Niche: Utilize high-resolution technologies, including single-cell sequencing and spatial transcriptomics, to characterize the pelvic neuro-immune cellular landscape in both healthy conditions and across various MSD subtypes. Biomarker Discovery and Validation: Establish well-phenotyped longitudinal cohorts to identify and validate candidate neuroimmune biomarkers capable of predicting disease trajectory, subtype classification, and potential responsiveness to immunomodulatory or neuromodulatory interventions. Biomarker Discovery and Validation: Establish well-phenotyped longitudinal cohorts to identify and validate candidate neuroimmune biomarkers capable of predicting disease trajectory, subtype classification, and potential responsiveness to immunomodulatory or neuromodulatory interventions. Pioneering Precise Therapeutic ParadigmsFuture trials should prioritize phenotype-guided immunomodulation, stratifying patients by neuro-immune signatures (e.g., “peripheral inflammatory,” “central neuroinflammatory,” or “autoimmune-dominant” subtypes). Combinatorial approaches integrating neuromodulation with immunomodulation—such as vagus nerve stimulation alongside anti-cytokine therapy—may synergistically restore systemic and local immune balance.Ultimately, the neuro-immune axis represents a actionable frontier for targeted therapy in MSD. By leveraging advances in immunology, neurobiology, and precision medicine, we may shift from symptomatic management toward mechanism-driven, personalized interventions that address the root causes of sexual dysfunction. Pioneering Precise Therapeutic Paradigms Future trials should prioritize phenotype-guided immunomodulation, stratifying patients by neuro-immune signatures (e.g., “peripheral inflammatory,” “central neuroinflammatory,” or “autoimmune-dominant” subtypes). Combinatorial approaches integrating neuromodulation with immunomodulation—such as vagus nerve stimulation alongside anti-cytokine therapy—may synergistically restore systemic and local immune balance. Ultimately, the neuro-immune axis represents a actionable frontier for targeted therapy in MSD. By leveraging advances in immunology, neurobiology, and precision medicine, we may shift from symptomatic management toward mechanism-driven, personalized interventions that address the root causes of sexual dysfunction. Authors’ contributions Zheng Hu and Jun Luo contributed equally as co-first authors. Jinming Chen served as the corresponding author, responsible for the conception, overall supervision, and critical revision of the manuscript.Jianyun Lou, Juntao Deng, and Zitao Gong participated in the literature review, drafting, and intellectual discussion of the manuscript.All authors reviewed and approved the final version of the manuscript. Funding This work was supported by the Science and Technology Program of Jiangxi Provincial Health Commission (Grant No. 202310744). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zheng Hu and Jun Luo are contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.